<DOC>
	<DOCNO>NCT00064207</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy gemcitabine use different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving treatment surgery may kill tumor cell remain surgery . It yet know whether give gemcitabine together radiation therapy effective gemcitabine alone follow surgery treat pancreatic cancer . PURPOSE : This randomized phase II/III trial study well give gemcitabine together radiation therapy work compare gemcitabine alone treat patient undergone surgery pancreatic cancer .</brief_summary>
	<brief_title>Gemcitabine Radiation Therapy Compared With Gemcitabine Alone Treating Patients Who Have Undergone Surgery Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Phase II : - Determine feasibility gemcitabine follow chemoradiotherapy gemcitabine v gemcitabine alone prior curative resection patient pancreatic head adenocarcinoma . - Compare tolerability regimen , term acute late toxicity , patient . Phase III : - Compare disease-free overall survival patient treat regimen . - Compare quality life patient treat regimen . - Compare toxicity regimens patient . - Determine site recurrence patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord ECOG/WHO performance status ( 0-1 v 2 ) , participate center , N stage ( N0 vs N1 v NX ) . Patients randomize 1 2 treatment arm . - Arm I : Within 8 week prior surgical resection , patient receive gemcitabine IV 30 minute day 1 , 8 , 15 . Treatment repeat every 4 week 2 course . Patients receive additional gemcitabine IV 30 minute day 57 , 64 , 71 , 78 , 85 , 92 . Beginning day 57 , patient also undergo radiotherapy daily , 5 day week , 6 week . Treatment continue absence disease progression unacceptable toxicity . - Arm II : Patients receive gemcitabine IV 30 minute day 1 , 8 , 15 . Treatment repeat every 4 week 4 course . Quality life ( QOL ) assess arm , accord follow schedule : - Arm I : QOL assess baseline ; 3 week begin chemoradiotherapy ; completion chemoradiotherapy ; every 3 month 2 year ; every 6 month 1 year . - Arm II : QOL assess baseline ; 12 week ; 16 week ; every 3 month 2 year ; every 6 month 1 year . Patients follow every 3 month 2 year every 6 month thereafter . PROJECTED ACCRUAL : A total 538 patient ( 269 per treatment arm ) accrue study within 3 year .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm pancreatic head adenocarcinoma Prior pancreaticoduodenectomy require Documented histological examination surgical margin ( R0 ) , include retroperitoneal margin Performed within past 8 week Any number lymph node ( le 10 OR 10 ) allow No periampullary cancer PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 OR WHO 02 Life expectancy Not specify Hematopoietic WBC great 3,500/mm^3 Platelet count great 150,000/mm^3 Hemoglobin great 9.0 g/dL Hepatic Bilirubin less 1.5 time normal AST ALT less 3.0 time normal Renal Creatinine le 1.2 mg/dL Other Not pregnant nursing Fertile patient must use effective contraception No prior concurrent malignancy except basal cell skin cancer carcinoma situ cervix No psychological , familial , sociological , geographical condition would preclude study compliance followup PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy Chemotherapy No prior chemotherapy No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy No prior radiotherapy Surgery See Disease Characteristics Recovered prior surgery Other No concurrent anticancer agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage I pancreatic cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
</DOC>